{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"6.7","value":"4.3"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"4.0","value":"1.9"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"8.5","value":"2.3"},{"groupId":"OG003","lowerLimit":"5.5","upperLimit":"6.9","value":"6.2"},{"groupId":"OG004","lowerLimit":"7.2","upperLimit":"7.2","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"description":"Estimated using the Kaplan-Meier method.From the date of the treatment start to the date of death or to the date of last follow-up if patients are alive at the time of data collection","dispersionType":"Full Range","groups":[{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n70 mg twice daily.\n\nDS-1594b: Given DS-1594b PO","id":"OG000","title":"Phase I (DS-1594b) Cohort 1"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n50 mg twice daily.\n\nDS-1594b: Given DS-1594b PO","id":"OG001","title":"Phase I (DS-1594b) Cohort 2"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n20 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"OG002","title":"Phase I (DS-1594b) Cohort 3"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n50 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"OG003","title":"Phase I (DS-1594b) Cohort 4"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n100 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"OG004","title":"Phase I (DS-1594b) Cohort 5"},{"description":"Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nDS-1594b: Given DS-1594b PO","id":"OG005","title":"Phase 2 Cohort A and B (DS-1594b)"},{"description":"Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nDS-1594b: Given DS-1594b PO\n\nAzacitidine: Given IV or SC\n\nVenetoclax: Given PO","id":"OG006","title":"Phase 2 Cohort C (DS-1594b, Venetoclax, Azacitidine)"},{"description":"Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.\n\nDS-1594b: Given DS-1594b PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT\n\nDexamethasone: Given PO or IV\n\nFilgrastim: Given SC\n\nLeucovorin: Given IV or PO\n\nMesna: Given IV\n\nMethotrexate: Given IT\n\nPrednisone: Given PO\n\nRituximab: Given IV\n\nVincristine: Given IV","id":"OG007","title":"Phase 2 Cohort D (DS-1594b, Mini-HCVD)"}],"paramType":"MEDIAN","populationDescription":"Participant were only enrolled in the phase 1 portion of this study. The study was terminated early and did not move on to Phase 2.","reportingStatus":"POSTED","timeFrame":"Up to the date of death or last follow-up, approximately 2 years, 7 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}